GB-115
EmergingRussian dipeptide CCK-B receptor antagonist developed at the Zakusov Institute (Seredenin / Garibova lab). | Peptide · Intranasal
Aliases (4)
▸ Overview TL;DR
Russian dipeptide CCK-B receptor antagonist developed at the Zakusov Institute (Seredenin / Garibova lab). Anxiolytic without GABA involvement — different mechanism from Selank, narrower spectrum, almost exclusively studied in Russian preclinical and small-N clinical work. For Dylan: NOT-RELEVANT. Selank already covers the anxiolytic role with better data, broader mechanism, and reliable sourcing. GB-115 is a curiosity / panic-disorder-specific tool, not a stack addition.
▸ Mechanism of action
Plain English: Cholecystokinin (CCK) is a peptide your gut famously uses to signal fullness — but a shorter form (CCK-4) and a brain-active form (CCK-8) act in the cortex and amygdala via two receptor subtypes: CCK-A (gut, satiety) and CCK-B (brain, panic/anxiety). Stimulating CCK-B with injected CCK-4 in healthy volunteers produces full-blown panic attacks within seconds — it's literally the experimental panic-induction model used in psychiatric pharmacology. GB-115 is a small synthetic dipeptide that sits on the CCK-B receptor and blocks it, dampening the panic/anxiety axis WITHOUT touching the GABA brake (which Selank, benzos, and phenibut all hit) and WITHOUT touching the serotonin or opioid systems. The result, per Russian preclinical and small clinical work, is a clean anxiolytic effect with no sedation and minimal cognitive footprint — the trade-off being it ONLY works on the CCK panic axis, so its efficacy depends on whether your anxiety is CCK-mediated.
Detailed mechanism:
Selective CCK-B (CCK2) receptor antagonism — The dominant and possibly only meaningful pharmacological action. CCK-B receptors are densely expressed in cortex, amygdala, hippocampus, and PAG (panic circuitry). Endogenous CCK-4 and CCK-8 activate these receptors during stress / panic states; antagonism reduces the panic / anxiety output without affecting CCK-A (gut, satiety) signaling.
No GABAergic activity — Distinguishes GB-115 from benzodiazepines, Selank (GABA-A PAM), phenibut (GABA-B agonist), and gabapentinoids. No tolerance / dependence pathway via GABA receptor downregulation.
No direct monoamine effects — Unlike Selank (which touches 5-HT, DA, NE indirectly) or SSRIs / SNRIs, GB-115 does not modify serotonin, dopamine, or noradrenaline transmission directly.
Possible mild antidepressant signature in Russian preclinical models — Some Seredenin/Garibova lab papers report antidepressant-like effects in forced-swim and tail-suspension models. Mechanism unclear; likely downstream of CCK-B blockade reducing chronic stress signaling.
No documented neurotrophic effect — Unlike Selank / Semax (which upregulate BDNF), GB-115 is not characterized as a neurotrophic compound. Pure receptor-antagonist profile.
Pharmacokinetics: Sparse data. Russian sources cite sublingual administration with rapid onset; plasma half-life and bioavailability not well-published in English-accessible literature. Active metabolite profile unclear.
▸ Pharmacokinetics No data
▸Quality indicators4 checks
▸ What to expect Generic
- 1Week 1Injection / administration protocol established. Tolerability check.
- 2Week 2-4Early onset of effect — subtle in most users, noticeable in responders.
- 3Week 4-8Peak benefit window for most peptide cycles.
- 4Week 8+Cycle decision point: continue, taper, or break.
▸ Side effects + safety
- Common (>10% users): Reported as minimal in Russian sources. Possible mild headache, mild GI discomfort.
- Less common (1-10%): Sparse data; Russian sources report negligible adverse events in small clinical samples.
- Rare-serious (<1%): No documented serious organ toxicity, dependence, withdrawal, or abuse pattern in available literature. Caveat: the absence of evidence reflects sparse study volume, not necessarily a clean safety signature. Long-term safety in healthy users is essentially uncharacterized.
- Specific watch periods: Unstudied. If used, treat as research-chem and run baseline labs + 4-week / 12-week follow-up (LFTs, CBC, kidney panel) at minimum.
▸References3 sources
Cholecystokinin (CCK) receptor antagonists in panic disorder — Western pharmacology context
background on the broader CCK-B antagonist class and its Western Phase II trial history
RUPharma GB-115 product listing (when in stock)
sourcing reference
CosmicNootropic GB-115 listing (when in stock)
sourcing reference